Clinical Trial Update: Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the tolerability of pegloticase (Krystexxa) given with a shorter infusion duration in subjects with uncontrolled gout who are receiving…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout

Drugs mentioned

• KRYSTEXXA (pegloticase)

Snippet

Sponsor: Amgen | Conditions: Chronic Uncontrolled Gout, Gout | Phase 4 | Status: COMPLETED | Results posted: 2025-01-07